

Simplexa® Bordetella Direct Kit
Direct detection and differentiation of Bordetella pertussis and Bordetella parapertussis.

Overview
Background
Pertussis, commonly called whooping cough, is a highly contagious disease of the respiratory system caused by small gram negative bacteria; Bordetella pertussis and Bordetella parapertussis. Clinically, it presents with a prolonged cough and patients with classic disease often have episodes of violent cough that may be followed by an inspiratory whoop and vomiting. There were 48,227 cases reported in the United States in 2012, making it the year with the highest number of reported cases since 1955.1 The World Health Organization estimates that there are 50 million whooping cough cases worldwide each year, resulting in 350,000 deaths.2,3 Pertussis can be detected among all age groups (e.g., neonates, children, adolescents and adults). A great majority of these cases are caused by Bordetella pertussis; however, up to 20% of cases are caused by Bordetella parapertussis, which can present clinically as a milder pertussis-like disease.4
1. Centers for Disease Control Data. Available at: https://www.cdc.gov/pertussis/outbreaks/trends.html
2. Kerr et al. Eur J Clin Microbiol Infect Dis. 2000. 19:77-88.
3. Loeffelholz, M.J. J. Clin Microbiol. 2012. 50:2186-2190.
4. Leber, A.L. Clin Lab Med. 2014. 34:237-255.
Why to choose it
A CLIA moderate complexity assay for the direct detection and differentiation of the B. pertussis IS481 and B. parapertussis IS1001 repeat elements. The assay improves efficiency with a true sample-to-answer workflow without DNA extraction.
For use on
Benefits
Simple and Dependable Bordetella Testing
The Simplexa® Bordetella Direct assay provides results in about an hour from nasopharyngeal specimens without the need for DNA isolation.
Reliable performance that you can count on
In a thorough study of over 1300 samples, our Simplexa® Bordetella Direct assay showed a positive percent agreement greater than 91% and a negative percent agreement greater than 97% for both Bordetella pertussis and Bordetella parapertussis.
Simplexa® Bordetella Direct Clinical Agreement Study
Specimen | Positive % Agreement | Negative % Agreement |
---|---|---|
SpecimenBordetella pertussis
prospective fresh samples |
Positive % Agreement100.0% (36/36) 95% CI: 90.4% to 100.0% |
Negative % Agreement97.9% (326/333) 95% CI: 95.7% to 99.0% |
SpecimenBordetella pertussis
prospective frozen samples |
Positive % Agreement91.9% (68/74) 95% CI: 83.4% to 96.2% |
Negative % Agreement98.7% (1026/1039) 95% CI: 97.9% to 99.3% |
SpecimenBordetella parapertussis
prospective fresh samples |
Positive % Agreement100.0% (2/2) 95% CI: 34.2% to 100.0% |
Negative % Agreement100.0% (174/174) 95% CI: 97.8% to 100.0% |
SpecimenBordetella parapertussis
prospective frozen samples |
Positive % Agreement100.0% (13/13) 95% CI: 77.2% to 100.0% |
Negative % Agreement99.6% (1096/1100) 95% CI: 99.1% to 99.9% |
SpecimenBordetella parapertussis
contrived frozen samples |
Positive % Agreement100.0% (56/56) 95% CI: 93.6% to 100.0% |
Negative % Agreement100.0% (56/56) 95% CI: 93.6% to 100.0% |
Education
Ordering info
Product | Code | Reactions |
---|---|---|
Product Simplexa® Bordetella Direct |
Code MOL2750 | Reactions 24 |
Product Simplexa® Bordetella Positive Control Pack |
Code MOL2760 | Reactions 10 |
Our repository
All the answers you need.
Access our database to find:
instructions for use, safety data sheets,
assay protocols and more.